YY Inc. (YY) Forms $95.40 Double Top; 6 Analysts Bullish Endocyte, Inc. (ECYT)

April 20, 2018 - By Clifton Ray

YY Inc. (YY) formed double top with $99.22 target or 4.00% above today’s $95.40 share price. YY Inc. (YY) has $6.03B valuation. The stock decreased 0.37% or $0.35 during the last trading session, reaching $95.4. About 753,083 shares traded. YY Inc. (NASDAQ:YY) has risen 125.46% since April 20, 2017 and is uptrending. It has outperformed by 113.91% the S&P500.

Among 6 analysts covering Endocyte (NASDAQ:ECYT), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Endocyte had 11 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Hold” on Friday, June 2. The firm has “Hold” rating by Cowen & Co given on Monday, October 2. The rating was downgraded by Cowen & Co on Monday, June 5 to “Market Perform”. The firm has “Outperform” rating given on Tuesday, October 3 by Wedbush. The firm has “Outperform” rating given on Wednesday, November 4 by RBC Capital Markets. The firm earned “Outperform” rating on Thursday, January 21 by Credit Suisse. The stock has “Outperform” rating by Cowen & Co on Tuesday, February 27. RBC Capital Markets maintained Endocyte, Inc. (NASDAQ:ECYT) on Wednesday, August 5 with “Outperform” rating. Wedbush downgraded Endocyte, Inc. (NASDAQ:ECYT) on Monday, June 5 to “Neutral” rating. See Endocyte, Inc. (NASDAQ:ECYT) latest ratings:

13/04/2018 Broker: Jefferies Rating: Buy New Target: $17 Initiates Coverage On
09/03/2018 Broker: Wells Fargo Rating: Outperform New Target: $20 Initiates Coverage On
27/02/2018 Broker: Cowen & Co Old Rating: Market Perform New Rating: Outperform Upgrade

Among 14 analysts covering YY Inc (NASDAQ:YY), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. YY Inc has $180.0 highest and $45 lowest target. $121.50’s average target is 27.36% above currents $95.4 stock price. YY Inc had 24 analyst reports since August 17, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, November 15 by Jefferies. The rating was upgraded by Instinet on Thursday, January 18 to “Buy”. The company was initiated on Monday, November 28 by Bank of America. Jefferies maintained the shares of YY in report on Friday, June 16 with “Hold” rating. The firm earned “Hold” rating on Tuesday, October 3 by Jefferies. Citigroup initiated YY Inc. (NASDAQ:YY) on Tuesday, February 20 with “Buy” rating. The firm has “Buy” rating given on Tuesday, July 4 by Bank of America. The rating was upgraded by JP Morgan on Thursday, November 16 to “Overweight”. Nomura upgraded YY Inc. (NASDAQ:YY) on Wednesday, January 17 to “Buy” rating. On Monday, August 17 the stock rating was downgraded by Pacific Crest to “Sector Weight”.

Analysts await YY Inc. (NASDAQ:YY) to report earnings on May, 9. They expect $1.31 earnings per share, down 2.24% or $0.03 from last year’s $1.34 per share. YY’s profit will be $82.75 million for 18.21 P/E if the $1.31 EPS becomes a reality. After $1.77 actual earnings per share reported by YY Inc. for the previous quarter, Wall Street now forecasts -25.99% negative EPS growth.

Since March 9, 2018, it had 0 insider purchases, and 1 insider sale for $45,677 activity. Leamon Christopher P sold $45,677 worth of Endocyte, Inc. (NASDAQ:ECYT) on Friday, March 9.

Investors sentiment increased to 1.36 in Q4 2017. Its up 1.04, from 0.32 in 2017Q3. It improved, as 11 investors sold Endocyte, Inc. shares while 14 reduced holdings. 19 funds opened positions while 15 raised stakes. 19.91 million shares or 140.76% more from 8.27 million shares in 2017Q3 were reported. Axa, France-based fund reported 23,500 shares. California Pub Employees Retirement Sys invested in 258,100 shares or 0% of the stock. Reilly Fincl Advsr Limited Liability Corp holds 0% or 2,000 shares in its portfolio. Bb&T Securities Limited Liability accumulated 0% or 20,750 shares. Pinnacle Associate has 16,395 shares. Royal Savings Bank Of Canada invested in 0% or 12,882 shares. Meeder Asset Mngmt holds 0% or 235 shares in its portfolio. Eam Investors Ltd Limited Liability Company has 98,034 shares. Susquehanna Group Ltd Liability Partnership holds 17,949 shares or 0% of its portfolio. Alpine Glob Limited Co has 33,675 shares. Baker Bros Advsrs L P holds 0.04% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT) for 1.09M shares. Financial Bank Of America De owns 67,510 shares or 0% of their US portfolio. Morgan Stanley holds 0% in Endocyte, Inc. (NASDAQ:ECYT) or 166,663 shares. Texas-based Dimensional Fund Lp has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Gp One Trading Limited Partnership owns 13,578 shares.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts